ABSTRACT
Transcutanous aortic valve replacement with Medtronic CoreValve in a publicprivate partnership hospital complex both death and hospitalisation. Reported 30 day mortality ranges from 5 -15% (9) (10) (11) (12) (13) with 1 year survival ranging from 60 -80%. (8, 10, (14) (15) (16) Improvement in symptomatology and valvular hemodynamic were also sustained at 2 years of follow-up. (10, 13, 16) The long-term durability of TAVI valves still has to be ascertained, but the 3 -5 year results are promising. (15) Initial results with the Medtronic CoreValve device (Medtronic Inc. Minneapolis, USA) were inferior to those of the rival device. Increasing experience revealed a trend of improved combined safety endpoints. (17) Recent results from the ADVANCE registry have shown procedural success rate of 98%, with 6 month and 1 year survival rates being 88% and 82% respectively. 
INTRODUCTION
In the developed world, aortic stenosis (AS) is the most frequent type of valvular heart lesion found in the elderly. It primarily presents as calcific aortic stenosis in adults of advanced age above 65 years. (1, 2) In asymptomatic individuals with severe AS, average event-free survival at 2 years ranges from 20 -50%. However, in symptomatic patients the prognosis is dismal with survival rates of 15 -50% at 5 years. (3) (4) (5) Aortic valve replacement is the definitive therapy for severe AS.
However, many patients with AS and coexisting conditions are not candidates for surgical aortic valve replacement. In the Euro Heart Survey 33% of 216 patients >75 years presenting with symptomatic severe AS were not referred for surgery. (6) Transcatheter aortic valve implantation (TAVI) is an alternative, less invasive treatment for high risk patients with symptomatic severe AS. In the absence of anatomical contraindications, transfemoral approach is the preferred access route with a procedural success rate of >95%. (7) (8) (9) (10) In selected patients, TAVI reduced the rates of TAVI procedure was performed as described by Grube, et al. (20) and 
DISCUSSION
In our institution severe aortic stenosis represents 10.1% of all significant valvular lesions. Demographically, our study population included both first and third world individuals and subsequently showed a predominant age distribution less than 75 years which differs noticeably from experience in developed countries where patients are much older. (1, 2) In a geriatric population symptomatology may be difficult to interpret, but it is significant that only a minority of patients presented with classical symptoms of angina, syncope or palpitations. Our data have confirmed the adverse outcome of aortic stenosis if treated medically. Long term benefits after 10 years will, however, unlikely differ from conventional surgical valve replacement. For the foreseeable future SVR will be the treatment of choice in low risk patients and TAVI will be offered to moderate or high risk and relatively elderly patients. (22) In our experience, TAVI is a technically demanding interventional cardiologic procedure with a challenging learning curve and initial proctor guidance is a non-negotiable necessity. A multi-disciplinary approach towards patient selection was very meaningful. Medtronic Company and the academic public sector authorities in our center.
The incidence of peri-procedural complications in the form of atrioventricular conduction disturbance was not different from previously reported data. (9, 10, 12, 18) At 3 -15 months follow-up, mortality rates were also comparable to other studies. (12, 13, 15, 16) Our experience regarding short term mortality for valve-in-valve TAVI differs from other data. (23, 24) In 47 patients reported by Webb, et al.
the success rate was 98% with 30 day mortality of 17%. In 3 out of 8 fatalities non cardiac septicaemia was reported. In our limited experience none of the deaths were cardiac related but in 2 patients underlying non cardiac septicaemia was noted. Also, postprocedural death occurred much later in our patients. The significance of post-procedural septicaemia in this patient group probably warrants further investigation. In all the remaining patients, symptomatic improvement was noted. The declines in pro BNP values were substantial, although not significant but the small patient cohort may have had an influence on this result.
CONCLUSIONS
TAVI is technically, logistically and financially a very demanding procedure. Our initial experience with Medtronic CoreValve TAVI was acceptable with a good immediate success and low complication rate. The favourable procedural financial implications are important. Present day guidelines regarding patient selection to include only patients in the highest 10th percentile of risk preclude meaningful long term outcome assessment. (25) Conflict of interest: none declared.
